NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000000705

Registered date:14/05/2007

Phase II trial of gemcitabine and cisplatin in patients with completely resected stage IB-IIIA non-small-cell lung cancer.

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedin patients with completely resected stage IB-IIIA non-small-cell
Date of first enrollment2007/01/01
Target sample size20
Countries of recruitmentJapan
Study typeObservational
Intervention(s)

Outcome(s)

Primary Outcometreatment compliance rate is 70% or more.
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum80years-old
GenderMale and Female
Include criteria
Exclude criteriaPatients with incomplete resection, wedge resection, clinically significant cardiac dysfunction, active infection, Varicella, or critical complications, neurologic or psychiatric disorders, and patients who had had other cancers treated within the previous five years were ineligible. Pregnant woman were also ineligible. Patients decided to be unsuitable by the doctor was ineligible.

Related Information

Contact

public contact
Name Kazuhito Funai
Address Japan
Telephone
E-mail kfunai@hmedc.or.jp
Affiliation Hamamatsu University School of Medicine First Department of Surgery
scientific contact
Name Kazuya Suzuki
Address 1-20-1 Handayama, Higashi, Hamamatsu, 431-3192,Japan Japan
Telephone
E-mail
Affiliation Hamamatsu University School of Medicine First Department of Surgery